Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency

Hui Wen Yao, Li Chiu Wang, Hsien Yang Tsai, Yi Hsuan Fang, Chunfu Zheng, Shun Hua Chen, Sheng Min Hsu

研究成果: Article

摘要

Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.

原文English
頁(從 - 到)105-112
頁數8
期刊Journal of Leukocyte Biology
107
發行號1
DOIs
出版狀態Published - 2020 一月 1

指紋

Human Herpesvirus 1
Neutrophils
Virus Diseases
Leukocytes
Drug Therapy
Infection
Bortezomib
Neutropenia
Viral Load
Lymphoma
Apoptosis
Viruses
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Cell Biology

引用此文

Yao, Hui Wen ; Wang, Li Chiu ; Tsai, Hsien Yang ; Fang, Yi Hsuan ; Zheng, Chunfu ; Chen, Shun Hua ; Hsu, Sheng Min. / Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency. 於: Journal of Leukocyte Biology. 2020 ; 卷 107, 編號 1. 頁 105-112.
@article{68fe3b5e845a47268e10763b7a1162f2,
title = "Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency",
abstract = "Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.",
author = "Yao, {Hui Wen} and Wang, {Li Chiu} and Tsai, {Hsien Yang} and Fang, {Yi Hsuan} and Chunfu Zheng and Chen, {Shun Hua} and Hsu, {Sheng Min}",
year = "2020",
month = "1",
day = "1",
doi = "10.1002/JLB.4AB1019-495R",
language = "English",
volume = "107",
pages = "105--112",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "1",

}

Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency. / Yao, Hui Wen; Wang, Li Chiu; Tsai, Hsien Yang; Fang, Yi Hsuan; Zheng, Chunfu; Chen, Shun Hua; Hsu, Sheng Min.

於: Journal of Leukocyte Biology, 卷 107, 編號 1, 01.01.2020, p. 105-112.

研究成果: Article

TY - JOUR

T1 - Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency

AU - Yao, Hui Wen

AU - Wang, Li Chiu

AU - Tsai, Hsien Yang

AU - Fang, Yi Hsuan

AU - Zheng, Chunfu

AU - Chen, Shun Hua

AU - Hsu, Sheng Min

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.

AB - Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.

UR - http://www.scopus.com/inward/record.url?scp=85075385177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075385177&partnerID=8YFLogxK

U2 - 10.1002/JLB.4AB1019-495R

DO - 10.1002/JLB.4AB1019-495R

M3 - Article

C2 - 31729784

AN - SCOPUS:85075385177

VL - 107

SP - 105

EP - 112

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 1

ER -